Paul Conrad

Paul Conrad has extensive work experience in the biotechnology and pharmaceutical industries. Paul currently holds the position of Chief Business Officer at NextPoint Therapeutics, Inc., a role they have held since December 2021. Prior to this, they worked as a Corporate Strategy Advisor at Apic Bio, Inc. from July 2021 to December 2021.

From 2018 to 2021, Paul served as the Vice President of Corporate Development at bluebird bio. Before that, they were the Head of Immunology and Heme/Onc Transactions at Shire from June 2016 to January 2018. Paul also worked at Baxalta as the Senior Director of Global Business Development from July 2015 to July 2016 and at Baxter International Inc. as the Senior Director of Global Business Development from May 2015 to July 2015.

Paul's career began at AMAG Pharmaceuticals in 2008, where they held multiple roles including Senior Director of Business Development and Director of Program and Alliance Management until 2015. In the same year, they also worked briefly at Taligen Therapeutics and Immuneering Corporation. Prior to that, Paul worked as an Investment Consultant at Third Rock Ventures from 2007 to 2008.

Throughout their career, Paul has accumulated a wealth of experience and expertise in business development, corporate strategy, and program management within the biotechnology and pharmaceutical sectors.

Paul Conrad has a PhD in Chemical Engineering from the University of Wisconsin-Madison. Paul also holds a BSE in Chemical Engineering from Princeton University. In addition, they have obtained an MBA from Harvard Business School.